Paulson Wealth Management Inc. Has $1.15 Million Stock Holdings in Johnson & Johnson $JNJ

Paulson Wealth Management Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 40.9% in the second quarter, Holdings Channel.com reports. The firm owned 7,499 shares of the company’s stock after purchasing an additional 2,175 shares during the quarter. Paulson Wealth Management Inc.’s holdings in Johnson & Johnson were worth $1,145,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in JNJ. Greenup Street Wealth Management LLC lifted its stake in Johnson & Johnson by 3.1% in the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after acquiring an additional 60 shares during the last quarter. Ellis Investment Partners LLC increased its position in Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after buying an additional 62 shares during the period. Cypress Wealth Services LLC lifted its holdings in shares of Johnson & Johnson by 0.9% during the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after buying an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN boosted its position in shares of Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after acquiring an additional 64 shares during the period. Finally, Global Strategic Investment Solutions LLC grew its stake in shares of Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock valued at $294,000 after acquiring an additional 65 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.5%

Shares of JNJ stock opened at $186.92 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $450.33 billion, a P/E ratio of 18.04, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The stock’s fifty day simple moving average is $184.06 and its 200 day simple moving average is $168.42.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is currently 50.19%.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. UBS Group increased their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Argus set a $210.00 price target on Johnson & Johnson in a research report on Wednesday, October 15th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Finally, Bank of America boosted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research note on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $199.05.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.